Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Current Treatment Options in Neurology|June 21, 2007
Anticonvulsant hypersensitivity syndrome: identification and managementTricia Y TingClinical EEG and Neuroscience|May 14, 2025
Longitudinal EEG Characteristics of Anti-GAD65 Antibody Related Autoimmune EpilepsyTian Wang, Cameron Mohammadi, Robert K Shin, et al.Epilepsy & Behavior : E&B|February 25, 2020
Relationship of antiepileptic drugs to generic brittleness in patients with epilepsySharmila Das, Xiaohui Jiang, Wenlei Jiang, et al.Epilepsy & Behavior : E&B|February 12, 2022
Lack of association between generic brittleness and neuropsychiatric measures in patients with epilepsySharmila Das, Xiaohui Jiang, Wenlei Jiang, et al.Molecular Pharmaceutics|May 23, 2015
Biopharmaceutic Risk Assessment of Brand and Generic Lamotrigine TabletsSoundarya Vaithianathan, Siddarth Raman, Wenlei Jiang, et al.Epilepsy & Behavior : E&B|December 24, 2018
Exploring generic brittleness and the demographic factors for its susceptibility in patients with epilepsySharmila Das, Xia Pu, Xiaohui Jiang, et al.Pharmaceutical Research|February 28, 2020
Lack of Association of Generic Brittle Status with Genetics and Physiologic Measures in Patients with EpilepsySharmila Das, Dong Guo, Xiaohui Jiang, et al.Epilepsia|July 24, 2015
Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standardTricia Y Ting, Wenlei Jiang, Robert Lionberger, et al.Journal of Pharmaceutical Sciences|September 17, 2015
Effect of Common Excipients on the Oral Drug Absorption of Biopharmaceutics Classification System Class 3 Drugs Cimetidine and AcyclovirSoundarya Vaithianathan, Sam H Haidar, Xinyuan Zhang, et al.Journal of Pharmaceutical Sciences|March 30, 2016
Reply to "On the Effect of Common Excipients on the Oral Absorption of Class 3 Drugs"Soundarya Vaithianathan, Sam H Haidar, Xinyuan Zhang, et al.Pageof 2